Trials / Completed
CompletedNCT00136955
Irinotecan Study For Cervical Cancer
An Open Labeled, Single-Arm, Multicentre Phase II Study To Evaluate The Efficacy And Safety Of Weekly Irinotecan Plus Cisplatin As First-Line Chemotherapy For Advanced Or Recurrent Squamous Cell Carcinoma Of The Uterine Cervix
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 41 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- Female
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to evaluate the efficacy and safety of Irinotecan plus cisplatin as first-line chemotherapy for advanced or recurrent cervical cancer
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Irinotecan | An Open Labeled, Single-Arm, Multicentre Phase II Study To Evaluate The Efficacy And Safety Of Weekly Irinotecan (60mg/sqm, D1, 8, 15) Plus Cisplatin (60mg/sqm, D1) As First-Line Chemotherapy For Advanced Or Recurrent Squamous Cell Carcinoma Of The Uterine Cervix |
Timeline
- Start date
- 2004-06-01
- Primary completion
- 2008-05-01
- Completion
- 2008-05-01
- First posted
- 2005-08-29
- Last updated
- 2015-06-19
- Results posted
- 2009-06-25
Locations
5 sites across 1 country: Taiwan
Source: ClinicalTrials.gov record NCT00136955. Inclusion in this directory is not an endorsement.